Skip to main content
Journal for Immunotherapy of Cancer logoLink to Journal for Immunotherapy of Cancer
. 2020 Apr 28;8(1):e0737-3corr1. doi: 10.1136/jitc-2020-0737-3corr1

Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

PMCID: PMC7279654  PMID: 32345628

Wu H, Chen Y, Wang Z, et al. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. J Immunother Cancer 2019;7:264. doi: 10.1186/s40425-019-0737-3

In the article titled ‘Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers’, there is the following errors:

In the abstract, the sentence ‘Among twenty-one key genes involving in the regulation of DNA methylation, TET1-mutant (TET1-MUT) was enriched in patients responding to ICI treatment in the discovery cohort (p<0.001)’ should instead read ‘Among twenty-one key genes involving in the regulation of DNA methylation, TET1-mutant (TET1-MUT) was enriched in patients responding to ICI treatment in the discovery cohort (p=0.003)’

Additionally, in Figure 6:

  1. Line 5, ‘HLA-DQA1’ should be ‘HLA-DQA2’

  2. Line 51–69 (from ENDRB to TIGIT), the category of these genes ‘Other’ should be ‘Receptor’

  3. Line 70–75 (from ARG1 to PRF1), the category of these genes ‘Receptor’ should be ‘Other’.

The correct Figure 6 can be seen below:

graphic file with name jitc-2020-0737-3corr1ilf01.jpg


Articles from Journal for Immunotherapy of Cancer are provided here courtesy of BMJ Publishing Group

RESOURCES